Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on CG Oncology, Inc.. The associated price target remains the same with $75.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the promising outlook for CG Oncology, Inc. A significant update from the BOND-003 Cohort C study has demonstrated that cretostimogene, a treatment for high-risk non-muscle invasive bladder cancer (NMIBC), shows a durable benefit with a high complete response rate and prolonged remission in patients. This positions cretostimogene as a leading therapy, especially when compared to competitors like TAR-200, which has shown less favorable efficacy and safety profiles.
Furthermore, the early completion of enrollment in the pivotal PIVOT-006 trial indicates a de-risked expansion strategy and accelerates market capture. The seamless integration of cretostimogene into existing urology practices, coupled with its robust efficacy and clean safety profile, strengthens its potential as a dominant therapy in the NMIBC market. While regulatory challenges remain, the comprehensive data and strategic positioning suggest a substantial market opportunity, supporting the Buy rating.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CGON in relation to earlier this year.